Why the study?
Does modified Wenyang Buxin decoction added to routine therapy improve cardiac function and serum biomarkers in chronic heart failure patients?
Population
120 chronic heart failure (CHF) patients admitted to Zhejiang Province Rongjun Hospital
Comparison
150 mL of modified Wenyang Buxin decoction daily… vs Routine therapy
Design
RCT, randomly but equally distributed
Follow-up
2 months
Key result
Modified Wenyang Buxin decoction combined with routine therapy significantly improved left ventricular ejection fraction (58.98% vs 50.11%, p<0.001) compared to routine therapy alone in patients with chronic heart failure.
Authors
Loading...
May improve biomarkers and function as adjunct in small RCT; leaves open efficacy in larger outcome trials.
RCT (n=120)
Random number table
No
Does modified Wenyang Buxin decoction added to routine therapy improve cardiac function and serum biomarkers in chronic heart failure patients?
Absolute Event Rate: 58.98% vs 50.11%
p-value: p=<0.001
Modified Wenyang Buxin decoction added to routine therapy may improve cardiac function, biomarker profiles, and quality of life in patients with chronic heart failure.
Qian et al. (2022) conducted an RCT in Chronic heart failure (CHF) (n=120). Modified Wenyang Buxin decoction vs. Routine therapy was evaluated on Left ventricle ejection fraction (LVEF) (p=<0.001). Modified Wenyang Buxin decoction combined with routine therapy significantly improved left ventricular ejection fraction (58.98% vs 50.11%, p<0.001) compared to routine therapy alone in patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: